Drug Profile

EXP 1603

Alternative Names: EXP-1603

Latest Information Update: 28 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Sep 2024 No recent reports of development identified for phase-I development in Traumatic-brain-injuries in USA
23 Sep 2022 EXP 1603 is still in phase-I clinical trials for Traumatic brain injuries in USA (unspecified route) (Expesicor pipeline, September 2022)
17 Jul 2020 Phase-I clinical trials in Traumatic brain injuries in USA (unspecified route), prior to July 2020 (Expesicor pipeline, July 2020)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com